Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | IMpassion031: patient-reported outcomes

Nadia Harbeck • 14 Dec 2020
SABCS 2020
Breast Cancer Antibodies Atezolizumab
IMpassion031

Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, outlines patient-reported outcomes from the Phase III IMpassion031 trial (NCT03197935) of neoadjuvant atezolizumab and chemotherapy in early, triple-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Nadia Harbeck

4:02
Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trials
Nadia Harbeck • 20 Sep 2022
4:11
The latest in neo-adjuvant therapy for luminal breast cancer
Nadia Harbeck • 20 Sep 2022
2:35
Treatment options for high risk early breast cancer
Nadia Harbeck • 20 Sep 2022
0:55
The clinical impact of gene expression assays on early luminal breast cancer
Nadia Harbeck • 4 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals